Brain Implant Market Value Predicted To Reach US$ 7,895.4 Million By 2027 Covering Pre and Post COVID-19 Market Analysis: Acumen Research And Consulting
April 21, 2021 12:19 ET
|
Acumen Research and Consulting
LOS ANGELES, April 21, 2021 (GLOBE NEWSWIRE) -- The Global Brain Implant Market is expected to grow at a CAGR of around 9.2% from 2020 to 2027 and reach the market value of over US$ 7,895.4 Mn by...
ObsEva Announces Third Quarter 2019 Financial Results
November 07, 2019 01:10 ET
|
ObsEva SA
– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast...
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
October 31, 2019 02:00 ET
|
ObsEva SA
FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the...
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
September 03, 2019 01:00 ET
|
ObsEva SA
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial...
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban
July 17, 2019 12:00 ET
|
ObsEva SA
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA - July 17, 2019 – ObsEva SA (NASDAQ:...
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
June 19, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
June 04, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
April 29, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
November 28, 2018 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – November 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
October 03, 2018 01:00 ET
|
ObsEva SA
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety profile not different from placebo in IMPLANT 2 European MAA submission...